期刊文献+

低分子肝素治疗不稳定性心绞痛25例的护理

原文传递
导出
出处 《中国误诊学杂志》 CAS 2010年第14期3470-3471,共2页 Chinese Journal of Misdiagnostics
  • 相关文献

参考文献4

二级参考文献19

  • 1[1]Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337 (10) :688-98
  • 2[2]Samama MM, Bara L, Gouin-Thibault I, et al. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 1996;52 Suppl 7:8-14;discussion 14-15
  • 3[3]Monrad ES. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2000;85(8A):2C-9C
  • 4[4]Warkentin TE,Levine MN, Hirsh J,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5
  • 5[5]Davis R,Faulds D. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging 1997; 10 (4): 299-322
  • 6[6]Kereiakes DJ,Kleiman NS, Fry E, Mwawasi G, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141(3):348-52
  • 7[7]Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84(12) :1391-5
  • 8[8]Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction ( TIMI ) Trial-phase Ⅰ: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11(1):1-11
  • 9[9]Kereiakes DJ,Grines C,Fry E,et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13(4) :272-8
  • 10[10]Karsch KR,Preisack MB, Baildon R,et al. Low molecular weight heparin(reviparin)in percutaneous transluminal coronary angioplasty. Results of a randomiza, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Henparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996;28(6) :1437-43

共引文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部